Literature DB >> 11568903

Metastatic Ewing sarcoma/PNET of bone at diagnosis: prognostic factors--a report from Saudi Arabia.

R D Jenkin1, I Al-Fawaz, M O Al-Shabanah, A Allam, M Ayas, M Memon, S Rifai, H P Schultz.   

Abstract

BACKGROUND: To evaluate outcome and prognostic factors in Saudi Arabian patients with metastatic Ewing sarcoma and PNET of bone (PMES) at diagnosis. PROCEDURE: Ninety-nine of 304 (33%) consecutive patients with Ewing sarcoma and PNET of bone registered at our centre from 1975 to 1998, had metastatic disease at registration and 93 were available for analysis. The maximum x-axis diameter of the primary tumor was used as the measure of primary tumor size. Usually a trial of systemic treatment was undertaken before a decision was made on local treatment. Standard chemotherapy regimens were used in all treated patients. Forty-one (44%) patients did not receive radical local treatment due to an inadequate response to chemotherapy, or a decision not to undertake more than palliative treatment. Radical treatment of the primary site was radiation alone 41 (79%), resection alone 7 (13%), and resection and radiation 4 (8%).
RESULTS: The 5-year survival rates were 9% for all 93 evaluable patients, 16% for 52 patients who received chemotherapy and radical local treatment, 0% for 41 patients who received lesser treatment, 19% for 43 patients with lung metastases alone, and 0% (P = 0.002) for 50 patients with other sites involved. For 60 patients with imaging data, 5-year survivals were 34 and 0% when the maximum transverse diameter of the primary tumor was < 10 cm (N = 20) and > or = 10 cm (N = 40), respectively.
CONCLUSIONS: Small primary tumor size and the presence of lung metastases alone were the only significant favorable prognostic factors. Earlier diagnosis will be the basis for better results. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11568903     DOI: 10.1002/mpo.1214

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  5 in total

1.  High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma.

Authors:  M Engelhardt; R Zeiser; G Ihorst; J Finke; C I Müller
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

Review 2.  High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma.

Authors:  Lianne M Haveman; Roelof van Ewijk; Elvira C van Dalen; Willemijn B Breunis; Leontien Cm Kremer; Henk van den Berg; Uta Dirksen; Johannes Hm Merks
Journal:  Cochrane Database Syst Rev       Date:  2021-09-02

3.  Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

Authors:  Guillaume Odri; Pui-Pui Kim; François Lamoureux; Céline Charrier; Séverine Battaglia; Jérôme Amiaud; Dominique Heymann; François Gouin; Françoise Redini
Journal:  BMC Cancer       Date:  2014-03-10       Impact factor: 4.430

4.  Primary Ewing's Sarcoma of the Sinonasal Tract: A Case Report.

Authors:  Tomoharu Suzuki; Ryuji Yasumatsu; Torahiko Nakashima; Shuji Arita; Hidetaka Yamamoto; Takashi Nakagawa
Journal:  Case Rep Oncol       Date:  2017-01-19

5.  The clinical use of biomarkers as prognostic factors in Ewing sarcoma.

Authors:  Annmeik M van Maldegem; Pancras Cw Hogendoorn; Andrew B Hassan
Journal:  Clin Sarcoma Res       Date:  2012-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.